Protego Biopharma, Inc.
Protego Bio is a clinical-stage biotech developing first-in-class small molecule pharmacological chaperones for AL amyloidosis and other protein misfolding diseases.
Funding history
About Protego Biopharma, Inc.
How much funding has Protego Biopharma, Inc. raised?
Protego Biopharma, Inc. has raised $32.9M in total funding. The most recent round was Series B.
Where is Protego Biopharma, Inc. headquartered?
Protego Biopharma, Inc. is headquartered in San Diego, CA.
What does Protego Biopharma, Inc. do?
Protego Bio is a clinical-stage biotech developing first-in-class small molecule pharmacological chaperones for AL amyloidosis and other protein misfolding diseases.
What problem does Protego Biopharma, Inc. solve?
Protein misfolding diseases, from cardiomyopathy to AL amyloidosis, represent serious conditions with critical unmet medical needs.
What's Protego Biopharma, Inc.'s solution?
Protego develops first-in-class small molecule pharmacological chaperones designed to restore protein function.
What makes Protego Biopharma, Inc. different?
Its drug discovery integrates protein sciences, advanced computation, and medicinal chemistry, and it builds on the prior breakthrough success of tafamidis, discovered by its cofounders.
What makes Protego Biopharma, Inc. notable?
Founded by Dr. Jeffery Kelly and Dr. Richard Labaudinière, scientists tied to the development of tafamidis, a blockbuster Pfizer amyloidosis drug; the San Diego company raised a $130M Series B.
Leadership
❝ Cite this page
Free to use in articles, research, and reference works. Stable URL, will not change. Data on this page last updated August 26, 2026.